To evaluate efficacy and tolerability of combination of Losartan and Ramipril in the management of mild to moderate hypertensive patients with associated diabetes mellitus. The secondary objective was to evaluate the efficacy of the combination in reducing microalbuminuria.
The study was an open, non-comparative, multicentric clinical trial conducted in 7 centres in 325 patients. All the patients were treated with Losartan 50mg + Ramipril 2.5mg or Losartan 50mg + Ramipril 5mg once a day depending upon the baseline blood pressure for 12 weeks.
The data was evaluated on a total of 315 patients. The mean prestudy systolic BP was 160.56+ 14.44 which was significantly reduced to 126.85 + 9.78 at the end of 12 weeks (P<0.001). Similarly the mean diastolic BP was 98.91 + 8.33 at baseline which was significantly reduced to 79.82 + 5.42 at the end of 12 weeks (P< 0.001). A mean fall of 33.72 mmHg and 19.10mm Hg was observed in systolic and diastolic BP respectively which was statistically highly significant (P<0.001). The JNC-7 goal of blood pressure <130/80 was achieved in 79.05% patients. At the end of the therapy 20.8% patients achieved normoalbuminuria.
The fixed dose combination of Losartan and Ramipril showed good to excellent efficacy response in 98.10% patients and achieved a target blood pressure of 130/80 mm Hg in 79.05% patients and 98.41% patients reported good to excellent tolerability. The combination reduced the urinary albumin excretion in majority of the patients with microalbuminuria and proteinuria.
Better control of blood pressure and reduces microalbuminuria.
D.R. Pawar, None.